Literature DB >> 15385439

Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes.

Nicholas J Bray1, Luke Jehu, Valentina Moskvina, Joseph D Buxbaum, Stella Dracheva, Vahram Haroutunian, Julie Williams, Paul R Buckland, Michael J Owen, Michael C O'Donovan.   

Abstract

The epsilon4 haplotype of APOE is the only undisputed genetic risk factor for late-onset Alzheimer's disease (LOAD). It has been proposed that at least two other polymorphisms in the promoter of the APOE gene (-219G>T and -491A>T) might also contribute to disease susceptibility, and modulate the impact of structural changes in the ApoE protein, by altering its expression. In order to assess the extent of cis-acting influences on APOE expression in human brain, highly quantitative measures of allele discrimination were applied to cortical RNA from individuals heterozygous for the epsilon alleles. A small, but significant, increase in the expression of epsilon4 allele was observed relative to that of the epsilon3 and epsilon2 alleles (P<0.0001). Similar differences were observed in brain tissue from confirmed LOAD subjects, and between cortical regions BA10 (frontopolar) and BA20 (inferior temporal). Stratification of epsilon4/epsilon3 allelic expression ratios according to heterozygosity for the -219G>T promoter polymorphism revealed significantly lower relative expression of haplotypes containing the -219T allele (P=0.02). Our data indicate that, in human brain, most of the cis-acting variance in APOE expression is accounted for by the epsilon4 haplotype, but there are additional, small, cis-acting influences associated with promoter genotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385439     DOI: 10.1093/hmg/ddh299

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  21 in total

1.  Association of ApoE and LRP mRNA levels with dementia and AD neuropathology.

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Neurobiol Aging       Date:  2011-06-15       Impact factor: 4.673

2.  Detection of cis-acting regulatory SNPs using allelic expression data.

Authors:  Rui Xiao; Laura J Scott
Journal:  Genet Epidemiol       Date:  2011-07-18       Impact factor: 2.135

3.  Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice.

Authors:  Nga Bien-Ly; Anna K Gillespie; David Walker; Seo Yeon Yoon; Yadong Huang
Journal:  J Neurosci       Date:  2012-04-04       Impact factor: 6.167

Review 4.  Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease.

Authors:  Massimo Tabaton; Alessandra Piccini
Journal:  Int J Exp Pathol       Date:  2005-06       Impact factor: 1.925

5.  The complex interaction between APOE promoter and AD: an Italian case-control study.

Authors:  Alessandra Bizzarro; Davide Seripa; Adele Acciarri; Maria Giovanna Matera; Alberto Pilotto; Francesco Danilo Tiziano; Christina Brahe; Carlo Masullo
Journal:  Eur J Hum Genet       Date:  2009-01-28       Impact factor: 4.246

6.  Epigenetic signature and enhancer activity of the human APOE gene.

Authors:  Chang-En Yu; Eiron Cudaback; Jessica Foraker; Zachary Thomson; Lesley Leong; Franziska Lutz; James Anthony Gill; Aleen Saxton; Brian Kraemer; Patrick Navas; C Dirk Keene; Thomas Montine; Lynn M Bekris
Journal:  Hum Mol Genet       Date:  2013-07-25       Impact factor: 6.150

Review 7.  Functional MAPT haplotypes: bridging the gap between genotype and neuropathology.

Authors:  Tara M Caffrey; Richard Wade-Martins
Journal:  Neurobiol Dis       Date:  2007-05-05       Impact factor: 5.996

Review 8.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

9.  APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure.

Authors:  Lynn M Bekris; Nichole M Galloway; Thomas J Montine; Gerard D Schellenberg; Chang-En Yu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

10.  In vitro and ex vivo analysis of CHRNA3 and CHRNA5 haplotype expression.

Authors:  Glenn A Doyle; Min-Jung Wang; Andrew D Chou; John U Oleynick; Steven E Arnold; Russell J Buono; Thomas N Ferraro; Wade H Berrettini
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.